Use of Levosimendan in Patients With Low Left Ventricular Ejection Fraction in Ordu/Turkey: Report of Experience with Mini Review
Mihriban Yalcin *
Department of Cardiovascular Surgery, Ordu State Hospital, Ordu, Turkey
Eda Godekmerdan
Department of Cardiovascular Surgery, Ordu State Hospital, Ordu, Turkey
Kaptanı Derya Tayfur
Department of Cardiovascular Surgery, Ordu State Hospital, Ordu, Turkey
Serkan Yazman
Department of Cardiovascular Surgery, Ordu State Hospital, Ordu, Turkey
Ahmet Ozyazicioglu
Department of Cardiovascular Surgery, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
*Author to whom correspondence should be addressed.
Abstract
Aims:To report the effect of prophylactic usage of levosimendan in patients with low left ventricular ejection fraction undergoing coronary artery bypass grafting (CABG).
Methods: We reported early results of 32 patients (26 male and 6 female; mean age 61.630 ± 9.653 years) who received preoperative levosimendan who underwent CABG with left ventricular ejection fraction (LVEF) of 35% or less between March 2014 and August 2016.
Results: All patients achieved to wean from cardiopulmonary bypass. In only four patients there was a need for intraaortic baloon pump (12.5%). Mortality was in 4 patients (12.5%). And six months after the operation all patients (discharged from hospital) were alive.
Conclusion: Preoperatively administration of the long-acting inotrope levosimendan might be feasible and have a favourable safety profile in patients with severely reduced LVEF undergoing CABG. We suggest that levosimendan may be useful in high-risk CABG patients.
Keywords: Coronary artery bypass greft, low cardiac output syndrome, levosimendan